Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Pulnovo Medical

    • Home
    • Pulnovo Medical
Company Deals

Pulnovo Medical Raises Tens of Millions in New Financing Round

Fineline Cube May 21, 2025

Wuxi-based Pulnovo Medical Limited, a developer of medical devices for hypertension and heart failure, announced...

Company Deals

Pulnovo Medical Raises USD 100M in Series C Financing for Global Expansion

Fineline Cube Mar 3, 2025

Wuxi-based Pulnovo Medical Limited, a developer of medical devices for pulmonary hypertension and heart failure,...

Company Medical Device

NMPA Approves Pulnovo Medical’s Novel Catheter for Treating Pulmonary Arterial Hypertension

Fineline Cube Dec 28, 2023

The National Medical Products Administration (NMPA) has granted marketing approval for Pulnovo Medical’s disposable circular...

Company Deals

Pulnovo Medical Raises ‘Tens of Millions’ in New Financing Round

Fineline Cube Nov 4, 2022

Pulnovo Medical, a pulmonary hypertension (PH) medical device maker based in Wuxi, has reportedly raised...

Recent updates

  • Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial
  • FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link
  • Leqvio Gets NMPA Nod for Monotherapy in China Hypercholesterolemia
  • Apeloa Partners with MindRank on AI Drug Development Platform
  • China Drug Administration Implementation Regulations Set for May 2026 Launch
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial

Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Company Drug

Leqvio Gets NMPA Nod for Monotherapy in China Hypercholesterolemia

Company Deals

Apeloa Partners with MindRank on AI Drug Development Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.